STRO - Sutro Biopharma Inc Stock Price, Fair Value and News

$3.57+0.02 (+0.56%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

STRO Price Action

Last 7 days

0.6%

Last 30 days

1.4%

Last 90 days

-10.6%

Trailing 12 Months

37.6%

STRO RSI Chart

STRO Valuation

Market Cap

291.0M

Price/Earnings (Trailing)

-2.34

Price/Sales (Trailing)

1.72

EV/EBITDA

-2.02

Price/Free Cashflow

-3.89

STRO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

STRO Fundamentals

STRO Revenue

Revenue (TTM)

169.4M

Rev. Growth (Yr)

146.89%

Rev. Growth (Qtr)

97.62%

STRO Earnings

Earnings (TTM)

-124.5M

Earnings Growth (Yr)

-24.64%

Earnings Growth (Qtr)

17.51%

STRO Profitability

EBT Margin

-63.06%

Return on Equity

-81.78%

Return on Assets

-25.45%

Free Cashflow Yield

-25.68%

STRO Investor Care

Shares Dilution (1Y)

35.42%

Diluted EPS (TTM)

-1.83

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	154.1M	169.4M	0	0
2023	74.5M	56.9M	48.6M	153.7M
2022	53.1M	53.2M	69.8M	67.8M
2021	50.2M	68.8M	59.5M	61.9M
2020	41.3M	40.2M	45.7M	42.7M
2019	41.3M	46.1M	50.5M	42.7M
2018	41.0M	31.3M	21.7M	36.7M
2017	57.7M	55.7M	53.7M	51.7M
2016	0	0	0	59.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About Sutro Biopharma Inc

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. Its pre-clinical product candidate STRO-003, a ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

CEO	Mr. William J. Newell J.D.
WEBSITE	sutrobio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	297

Sutro Biopharma Inc Frequently Asked Questions

What is the ticker symbol for Sutro Biopharma Inc? What does STRO stand for in stocks?

STRO is the stock ticker symbol of Sutro Biopharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sutro Biopharma Inc (STRO)?

As of Tue Oct 29 2024, market cap of Sutro Biopharma Inc is 290.97 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of STRO stock?

You can check STRO's fair value in chart for subscribers.

Is Sutro Biopharma Inc a good stock to buy?

The fair value guage provides a quick view whether STRO is over valued or under valued. Whether Sutro Biopharma Inc is cheap or expensive depends on the assumptions which impact Sutro Biopharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STRO.

What is Sutro Biopharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Oct 29 2024, STRO's PE ratio (Price to Earnings) is -2.34 and Price to Sales (PS) ratio is 1.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STRO PE ratio will change depending on the future growth rate expectations of investors.